TCTR20170109003尚未招募1 期
SINGLE DOSE CROSSOVER FULLY REPLICATE BIOEQUIVALENCE STUDY OF ATORVASTATIN CALCIUM TABLETS 80 MG IN HEALTHY, ADULT, HUMAN SUBJECTS UNDER FASTING CONDITIO
Bio-innova and Synchron Co., Ltd.0 个研究点目标入组 40 人开始时间: 2017年1月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1.Willingness to provide written informed consent to participate in the study.
- •2.Healthy Thai volunteers are between 18 to 55 years of age.
- •3.The Body Mass Index (BMI) ranges from 18 to 25 kg/m2.
- •4.Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring volunteers’ safety after the completion of the study.
- •5.Negative pregnancy test (urine) for women and no breast-feeding.
- •6.Negative pregnancy test (serum) for women.
- •7.Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician
排除标准
- •1.History or evidence of allergy or hypersensitivity to Atorvastatin calcium or other statin drugs or any related drugs or any of the excipients of this product.
- •2.Subject with B.P. is Systolic B.P < 90, ≥140 mm/Hg, Diastolic B.P < 60, ≥90 mm/Hg or pulse rate > 100 beats per minute.
- •3.Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).*
- •4.Serum creatinine greater than 1.5 times the ULRR. *
- •5.Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the ULRR.*
- •6.Investigations with blood samples of the subject show presence of disease markers of HIV, Hepatitis B or C Viruses or syphilis infection or Malaria.
- •7.Have more than one abnormal EKG which is considered as clinically significant.*
- •8.History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension, or glaucoma.
- •9.History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
- •10.Any major illness in the past 3 months or any significant ongoing chronic medical illness.
- •11.History of psychiatric disorder.
- •12.History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of the study.
- •13.History of usually smoking (more than 10 cigarettes per day), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study.
- •14.High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of the study.
- •15.History of consume grapefruit juice and/or grape fruit supplements and cannot stop at least 2 days before first drug administration and until the completion of the study.
- •16.Positive drug abused test in urine (Opioids, Cannabinoids).
- •17.Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera® must be discontinued at least 6 months) prior to receiving the first dose of study medication until the completion of the study.
- •18.History of difficulty in accessibility of veins in left or right arm.
- •19.Blood donation (one unit or 350 mL) within the past 3 months before the study.
- •20.Participation in any clinical study within the past 3 months before the study.
- •21.Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.
研究者
相似试验
尚未招募
不适用
A Single Dose Crossover Fully Replicate Bioequivalent Study of Atorvastatin Calcium Equivalent to 80-mg Tablets under Fasting Conditio1. Male/Female must be 18ᇋ years of age,body mass index (BMI) =18ᆭ kg/m2,inclusive.2. Must be in good health as determined by medical history,vital signs,and physical examination.3. Scree1. Known hypersensitivity to atorvastatin and its components.2. Past medical history of renal and hepatic insufficiency.3. Subject has a history of any illness that,in the opinion of the investigTCTR20161121002Ranbaxy (Thailand) Co., Ltd.40
已完成
不适用
Pharmacodynamics end point study on Tetracosactide InjectioCTRI/2021/04/032482Sun Pharmaceutical Medicare Limited48
尚未招募
不适用
A Single Dose Two-Way Crossover Bioequivalence Study of Desloratadine Tablets (5 mg) in Normal, Healthy, Adult, Human Subjects under Fasting Conditioormal,Healthy,Adult,Human SubjectsTCTR20180202001Sun Pharmaceutical Industries Limited32
已完成
1 期
A study comparing the level of absorption of sildenafil from Sildenafil 100 mg Oral Films versus Viagra® 100 mg tablets and the effect of food on absorption of sildenafil from Sildenafil 100 mg Oral Films in healthy meErectile dysfunctionUrological and Genital DiseasesISRCTN13297409IBSA Institut Biochimique S.A.45
已完成
1 期
Study of tadalafil 20 mg oral film and soft-gel capsules versus Cialis® (tadalafil) 20 mg tablet in healthy male volunteersISRCTN79039906IBSA Institut Biochimique SA15